 Home > Active Ingredient News > Digestive System Information > Puri Pharmaceuticals Pantoprazole Sodium for Injection Receives Health Canada Approval

Puri Pharmaceuticals Pantoprazole Sodium for Injection Receives Health Canada Approval

 Last Update: 2021-06-12
 Source: Internet
 Author: User

Tags

emerald health pharmaceuticals

enzyme product

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 3, Prism Pharmaceuticals issued an announcement stating that it had recently received a notice of approval of Pantoprazole Sodium for Injection issued by Health Canada.

Pantoprazole Sodium for Injection is a selective long-acting proton pump inhibitor.

The persulfoxide group is connected to the pyridine ring, which is relatively stable under neutral and weak acidic conditions, and is rapidly activated under strong acidic conditions, so that it has better selectivity for H+ and K+-ATPase.
This product can specifically inhibit the secretory microtubules formed by the apical membrane of parietal cells and the H+ and K+-ATPases on the tubular vesicles in the cytoplasm, causing irreversible inhibition of the enzymes, thereby effectively inhibiting the secretion of gastric acid.
It is suitable for active peptic ulcer (gastric, duodenal ulcer), reflux esophagitis and Zollinger-Ehrlich syndrome.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.